Cited by 203Bone Metabolism and DiseasesEstrogen and related hormone effectsBone health and osteoporosis research

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α.

Open access

Saika, Mieko, Inoue, Daisuke, Kido, Shinsuke, Matsumoto, Toshio·2001·Endocrinology

Open this paper in CoChat — free account

Abstract

Osteoprotegerin (OPG) is a recently identified member of the tumor necrosis factor (TNF) receptor superfamily that regulates bone mass through an inhibitory action on osteoclast differentiation and function. To determine its potential roles of OPG in pathological changes in bone metabolism caused by estrogen deficiency, we investigated effects of estrogen on OPG expression by a mouse stromal cell line, ST-2, in vitro. Treatment of ST-2 cells with 17beta-E(2) resulted in up-regulation of OPG expression at both the messenger RNA and protein levels. The effect was time and dose dependent and steroid specific. The stimulatory action of 17beta-E(2) on OPG expression appeared to be mediated by the estrogen receptor-alpha (ERalpha) subtype because stable overexpression of ERalpha, but not of ERbeta, enhanced the OPG induction by 17beta-E(2). Moreover, estrogen withdrawal after 5-day pretreatment, mimicking the event occurring in vivo at menopause, dramatically diminished the expression of OPG. These findings suggest that down-regulation of OPG after estrogen withdrawal contributes to the enhanced osteoclastic bone resorption and bone loss after menopause by enhancing RANK ligand-RANK system that lies downstream of a large number of bone-resorbing cytokines.

Integrity signals

Registry

Crossref · 10.1210/endo.142.6.8220

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G. J. M., Enmark, E., Pelto‐Huikko, M., Nilsson, S., & Gustafsson, J.-Α. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,802
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,345
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.
Lubahn, D. B., Moyer, J. S., GOLDING, T. S., Couse, J. F., Korach, K. S., & Smithies, O. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11162 · Cited by 1,902
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789

Show all 47 references

Sorted by citations

The complex role of estrogens in inflammation
Straub, R. H. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0001 · Cited by 1,950
Bone Remodeling
Hadjidakis, D., & Androulakis, I. I. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.035 · Cited by 1,531
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
Disorders of Bone Remodeling
Feng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 929
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 825
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
The bone remodelling cycle
Kenkre, J. E., & Bassett, J. H. D. (2018) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 775
Androgens and Bone
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues
Yeh, S., Tsai, M.-Y., Xu, Q., Mu, X., Lardy, H. A., Huang, K., Lin, H., Yeh, S.-D., Altuwaijri, S., Zhou, X., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212474399 · Cited by 683
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Major osteoporotic fragility fractures: Risk factor updates and societal impact
Pisani, P., Renna, M. D., Conversano, F., Casciaro, E., Paola, M. D., Quarta, E., Muratore, M., & Casciaro, S. (2016) · World Journal of Orthopedics · doi:10.5312/wjo.v7.i3.171 · Cited by 503
RANK Ligand and Osteoprotegerin
Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 408
PTH Differentially Regulates Expression of RANKL and OPG
Huang, J. C., Sakata, T., Pfleger, L. L., Bencsik, M., Halloran, B. P., Bikle, D. D., & Nissenson, R. A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301226 · Cited by 401
The role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 366
Bone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 354
The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.
Bord, S., Ireland, D. C., Beavan, S. R., & Compston, J. E. (2003) · Bone · doi:10.1016/s8756-3282(02)00953-5 · Cited by 333
Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 325
The Biology of Aseptic Osteolysis
Holt, G., Murnaghan, C., Reilly, J. H., & Meek, R. M. D. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e31804b4147 · Cited by 320
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Doherty, T. M., Fitzpatrick, L. A., Inoue, D., Qiao, J.-H., Fishbein, M. C., Detrano, R., Shah, P. K., & Rajavashisth, T. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0015 · Cited by 299
Self-citation
Estrogen Promotes Early Osteoblast Differentiation and Inhibits Adipocyte Differentiation in Mouse Bone Marrow Stromal Cell Lines that Express Estrogen Receptor (ER) or
Okazaki, R., Inoue, D., Shibata, M., Saika, M., Kido, S., Ooka, H., Tomiyama, H., Sakamoto, Y., & Matsumoto, T. (2002) · Endocrinology · doi:10.1210/endo.143.6.8854 · Cited by 282
Self-citation
Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency
Weitzmann, M. N., Roggia, C., Toraldo, G., Weitzmann, L., & Pacifici, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15687 · Cited by 271
The molecular actions of thyroid hormone in bone
Duncan Bassett, J. H., & Williams, G. R. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00144-9 · Cited by 261
The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 254
Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251
Role of RANKL and RANK in bone loss and arthritis
Jones, D. H., Kong, Y.-Y., & Penninger, J. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii32 · Cited by 225
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Correlates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205
In vitro Models of Bone Remodelling and Associated Disorders
Owen, R., & Reilly, G. C. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00134 · Cited by 201
Integrated Imaging Approach to Osteoporosis: State-of-the-Art Review and Update
Guglielmi, G., Muscarella, S., & Bazzocchi, A. (2011) · Radiographics · doi:10.1148/rg.315105712 · Cited by 193
Effect of Estrogen versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men
Khosla, S., Atkinson, E. J., Dunstan, C. R., & O’Fallon, W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8397 · Cited by 191
Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B
Weenig, R. H. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.12.006 · Cited by 182
Role of RANKL–RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications
Kohli, S. S., & Kohli, V. S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83401 · Cited by 181
Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen
Lu, L., & Tian, L. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0116 · Cited by 175
Recent advances in osteoclast biology and pathological bone resorption.
Blair, H. C., & Athanasou, N. A. (2004) · PubMed · doi:10.14670/hh-19.189 · Cited by 169
Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice
Mueller, S. O. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00105-9 · Cited by 157
N ew M olecules in the T umor N ecrosis F actor L igand and R eceptor S uperfamilies with I mportance for P hysiological and P athological B one R esorption
Lerner, U. H. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500202 · Cited by 147
Root resorption and the OPG/RANKL/RANK system: a mini review
Tyrovola, J. B., Spyropoulos, M. N., Makou, M., & Perrea, D. N. (2008) · Journal of Oral Science · doi:10.2334/josnusd.50.367 · Cited by 143
RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats
Ominsky, M. S., Li, X., Asuncion, F., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M. S., Tan, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 132
Osteoprotegerin and RANKL in the pathogenesis of Thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Meo, A., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040113 · Cited by 127
Estrogen Receptor α Mediates Proliferation of Osteoblastic Cells Stimulated by Estrogen and Mechanical Strain, but Their Acute Down-regulation of the Wnt Antagonist Sost Is Mediated by Estrogen Receptor β
Galea, G. L., Meakin, L. B., Sugiyama, T., Zebda, N., Sunters, A., Taipaleenmäki, H., Stein, G. S., van Wijnen, A. J., Lanyon, L. E., & Price, J. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.405456 · Cited by 126
Mechanisms of bone anabolism regulated by statins
Ruan, F., Zheng, Q., & Wang, J. (2012) · Bioscience Reports · doi:10.1042/bsr20110118 · Cited by 117
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
Delmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 117
Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts
Viereck, V., Gründker, C., Blaschke, S., Siggelkow, H., Emons, G., & Hofbauer, L. C. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10087 · Cited by 113
New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?
Tat, S. K., Pelletier, J.-P., Velasco, C. R., Padrines, M., & Martel-Pelletier, J. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.29 · Cited by 112
Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.
Viereck, V., Gründker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K.-H., Raddatz, D., Emons, G., & Hofbauer, L. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021877 · Cited by 110
RANK, RANKL and osteoprotegerin in arthritic bone loss
Bezerra, M. C., de Carvalho, J. F., Prokopowitsch, A. S., & Pereira, R. M. R. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000200004 · Cited by 99
Down-Regulation of Osteoclast Differentiation by Daidzein via Caspase 3
Rassi, C. M., Lieberherr, M., Chaumaz, G., Pointillart, A., & Cournot, G. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.4.630 · Cited by 98
Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders
Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91
RANKL and RANK as novel therapeutic targets for arthritis
Nakashima, T., & Penninger, J. M. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00016 · Cited by 89
Testosterone increases bone mineral density in female‐to‐male transsexuals: a case series of 15 subjects
Turner, A., Chen, T. C., Barber, T. W., Malabanan, A. O., Holick, M. F., & Tangpricha, V. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02125.x · Cited by 86
Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.
J�rgensen, H. L., Kusk, P., Madsen, B., Fenger, M., & Lauritzen, J. B. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0461-3 · Cited by 85
Pathophysiology of osteoporosis
Sipos, W., Pietschmann, P., Rauner, M., Kerschan‐Schindl, K., & Patsch, J. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0647-y · Cited by 85
Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene
Cheung, J., Mak, Y. T., Papaioannou, S., Evans, B. A., Fogelman, I., & Hampson, G. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770423 · Cited by 83
Postmenopausal Osteoporosis: A Literature Review
Bhatnagar, A., & Kekatpure, A. L. (2022) · Cureus · doi:10.7759/cureus.29367 · Cited by 79
OPG and sRANKL Serum Concentrations in Osteopenic, Postmenopausal Women After 2-Year Genistein Administration
Marini, H. R., Minutoli, L., Polito, F., Bitto, A., Altavilla, D., Atteritano, M., Gaudio, A., Mazzaferro, S., Frisina, A., Frisina, N., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080201 · Cited by 79
Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor κB legend with bone mineral density in older adults: the Rancho Bernardo Study
Stern, A., Laughlin, G. A., Bergstrom, J., & Barrett-Connor, E. L. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0753 · Cited by 76
Osteoclastic differentiation and function regulated by old and new pathways
Blair, H. C., & Zaidi, M. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9010-4 · Cited by 74
Circulating osteoprotegerin and receptor activator of NF-κB ligand system are associated with bone metabolism in middle-aged males.
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73
Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells.
Hofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72
A low dose of daidzein acts as an ERβ‐selective agonist in trabecular osteoblasts of young female piglets
Leblanc, A. L., Lieberherr, M., Colin, C., & Pointillart, A. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20008 · Cited by 72
Genetic Polymorphisms of OPG, RANK, and ESR1 and Bone Mineral Density in Korean Postmenopausal Women
Choi, J. Y., Shin, A., Park, S., Chung, H. W., Cho, S. I., Shin, C. S., Kim, H., Lee, K., Lee, K., Kang, C., et al. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0264-0 · Cited by 71
Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies
Bonura, F. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2021 · Cited by 66
Estrogen Receptor-Related Receptor α Impinges on the Estrogen Axis in Bone: Potential Function in Osteoporosis
Bonnelye, E., Kung, V., Laplace, C., Galson, D. L., & Aubin, J. E. (2002) · Endocrinology · doi:10.1210/en.2002-220095 · Cited by 62
Green tea polyphenol (−)‐epigallocatechin gallate suppressed the differentiation of murine osteoblastic MC3T3‐E1 cells
Kamon, M., Zhao, R., & Sakamoto, K. (2009) · Cell Biology International · doi:10.1042/cbi20090011 · Cited by 59
Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study
Taxel, P., Kaneko, H., Lee, S.-K., Aguila, H. L., Raisz, L. G., & Lorenzo, J. A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0452-7 · Cited by 58
Chronic Periodontitis and RANKL/OPG Ratio in Peri-Implant Mucosae Inflammation
Costa, L. C., da Fonseca, M. A., Pinheiro, A. D. R., Aguiar, T. R. D. S., Machado, A. N., Quinelato, V., Bonato, L. L., Aguiar, D. P., Vieira, T. C. S., de Almeida, F. L. D., et al. (2017) · Brazilian Dental Journal · doi:10.1590/0103-6440201801241 · Cited by 57
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis
Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Campagnuolo, G., Morony, S., Boyle, W. J., Zack, D. J., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10680 · Cited by 57
The Pathogenesis of Osteoarthritis Involves Bone, Cartilage and Synovial Inflammation: May Estrogen Be a Magic Bullet?
Karsdal, M. A., Bay‐Jensen, A., Henriksen, K., & Christiansen, C. (2012) · Menopause international · doi:10.1258/mi.2012.012025 · Cited by 56
Experimental and molecular docking studies of estrogen-like and anti-osteoporosis activity of compounds in Fructus Psoraleae
Cai, X.-Y., Zhang, Z., Xiong, J.-L., Yang, M., & Wang, Z. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114044 · Cited by 53
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
Hadji, P., Coleman, R. E., & Gnant, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.015 · Cited by 52
Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population
Trofimov, S., Pantsulaia, I., Kobyliansky, E., & Livshits, G. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500305 · Cited by 51
Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MG-63 cells
Jia, J., Zhou, H., Zeng, X., & Feng, S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6168 · Cited by 51
Effects of the Phytoestrogen Genistein on the Circulating Soluble Receptor Activator of Nuclear Factor κB Ligand-Osteoprotegerin System in Early Postmenopausal Women
Crisafulli, A., Altavilla, D., Squadrito, G., Romeo, A., Adamo, E. B., Marini, R., Inferrera, M. A., Marini, H. R., Bitto, A., D’Anna, R., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030891 · Cited by 50
Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women
Hofbauer, L. C., Schoppet, M., Schüller, P., Viereck, V., & Christ, M. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01969.x · Cited by 49
Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association
Martin, A., Xiong, J., Koromila, T., Ji, J. S., Chang, S. W., Song, Y. S., Miller, J. L., Han, C.-Y. E., Kostenuik, P. J., Krum, S. A., et al. (2015) · Bone · doi:10.1016/j.bone.2015.02.007 · Cited by 48
RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis
Giner, M., Rios, M. J., Montoya, M. J., Vázquez, M. Á., Naji, L., & Pérez‐Cano, R. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.11.005 · Cited by 43
Preventing Bone Loss and Weight Gain with Combinations of Vitamin D and Phytochemicals
Lai, C., Yang, J., Rayalam, S., Della‐Fera, M. A., Ambati, S., Lewis, R. D., Hamrick, M. W., Hartzell, D. L., & Baile, C. A. (2011) · Journal of Medicinal Food · doi:10.1089/jmf.2010.0232 · Cited by 43
Endogenous Glutamate in Association With Inflammatory and Hormonal Factors Modulates Bone Tissue Resorption of the Temporomandibular Joint in Patients With Early Rheumatoid Arthritis
Hajati, A., Alstergren, P. J., Näsström, K., Bratt, J., & Kopp, S. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.04.056 · Cited by 43
The role of estrogens in men and androgens in women
Khosla, S., & Bilezikian, J. P. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00087-7 · Cited by 43
Estrogen receptor‐β modulates synthesis of bone matrix proteins in human osteoblast‐like MG63 cells
Cao, L., Bu, R., Oakley, J. I., Kalla, S. E., & Blair, H. C. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10486 · Cited by 43
Molecular Aspects of Bone Remodeling
Alma, Y., Valdés‐Flores, M., Orozco, L., & Velzquez-Cruz, R. (2013) · InTech eBooks · doi:10.5772/54905 · Cited by 42
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Zaman, K., Thurlimann, B. J. K., Huober, J., Schönenberger, A., Pagani, O., Luthi, J., Simcock, M., Giobbie‐Hurder, A., Berthod, G., Genton, C. Y., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr448 · Cited by 42
The molecular etiology and treatment of glucocorticoid-induced osteoporosis
Peng, C.-H., Lin, W.-Y., Yeh, K., Chen, I., Wu, W., & Lin, M. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_233_20 · Cited by 41
Immunological Study on Circulating Murine Osteoprotegerin/Osteoclastogenesis Inhibitory Factor (OPG/OCIF): Possible Role of OPG/OCIF in the Prevention of Osteoporosis in Pregnancy
Yano, K., Shibata, O., Mizuno, A., Kobayashi, F., Higashio, K., Morinaga, T., & Tsuda, E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5745 · Cited by 41
In vitro evaluation of the direct effect of estradiol on human osteoblasts (HOB) and human mesenchymal stem cells (h-MSCs)
Silvio, L. D., Jameson, J., Gamie, Z., Giannoudis, P. V., & Tsiridis, E. E. (2006) · Injury · doi:10.1016/j.injury.2006.08.022 · Cited by 41
The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
Hadji, P., Coleman, R. E., Gnant, M., & Green, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds169 · Cited by 40
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene
Bashir, A. A., Mak, Y. T., Sankaralingam, S., Cheung, J., Nwa., M., Grigoriadis, A. E., Fogelman, I., & Hampson, G. (2005) · Steroids · doi:10.1016/j.steroids.2005.04.011 · Cited by 40
Ovariectomy increases RANKL protein expression in bone marrow adipocytes of C3H/HeJ mice
Beekman, K. M., Zwaagstra, M., Veldhuis‐Vlug, A. G., van Essen, H. W., den Heijer, M., Maas, M. M., Kerckhofs, G., Parac‐Vogt, T. N., Bisschop, P. H. L. T., & Bravenboer, N. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00142.2019 · Cited by 37
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases
Habibie, H., Adhyatmika, A., Schaafsma, D., & Melgert, B. N. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107941 · Cited by 37
Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells
Kallio, A., Guo, T., Lamminen, E., Seppänen, J., Kangas, L., Väänänen, H. K., & Härkönen, P. L. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.03.005 · Cited by 37
The Relationship between Serum Levels of Estradiol and Osteoprotegerin in Patients with Anorexia Nervosa
Ohwada, R., Hotta, M., Sato, K., Shibasaki, T., & Takano, K. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07-034 · Cited by 35
Nitric Oxide Donor Increases Osteoprotegerin Production and Osteoclastogenesis Inhibitory Activity in Bone Marrow Stromal Cells from Ovariectomized Rats
Wang, F.-S., Wang, C.-J., Chen, Y.-J., Huang, Y.-T., Huang, H.-C., Chang, P.-R., Sun, Y.-C., & Yang, K. D. (2004) · Endocrinology · doi:10.1210/en.2003-1074 · Cited by 35
Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women
Carlo, C. D., Tommaselli, G. A., Gargano, V., Sammartino, A., Bifulco, G., Tauchmanovà, L., Colao, A., & Nappi, C. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000227855.04732.7b · Cited by 34
The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women
Oh, K. W., Rhee, E., Lee, W., Kim, S. W., Oh, E. S., Baek, K. H., Kang, M. I., Choi, M. G., Yoo, H. J., & Park, S. W. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02090.x · Cited by 34
The effects of C161→T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-γ gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women
Rhee, E., Oh, K.-W., Lee, W., Kim, S.-Y., Oh, E.-S., Baek, K., Kang, M.-I., & Kim, S.-W. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.09.033 · Cited by 34
(Patho)physiology of cross-sex hormone administration to transsexual people: the potential impact of male-female genetic differences
Gooren, L. J., Kreukels, B. P. C., Lapauw, B., & Giltay, E. J. (2014) · Andrologia · doi:10.1111/and.12389 · Cited by 33
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole
Martinetti, A., Bajetta, E., Ferrari, L., Zilembo, N., Seregni, E. C., Vecchio, M. D., Longarini, R., Torre, I. L., Toffolatti, L., Paleari, D., et al. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00775 · Cited by 32

Authors: Saika, M., Inoue, D., Kido, S., & Matsumoto, T.
Affiliations: Tokushima University (JP)
Corresponding author: Inoue, Daisuke
ORCID: Inoue, Daisuke
Matsumoto, Toshio
Venue: Endocrinology
Publisher: The Endocrine Society
Published: 2001-06-01
Volume: 142
Issue: 6
Pages: 2205-2212
ISSN: 0013-7227 (ISSN-L)
1945-7170
DOI: 10.1210/endo.142.6.8220
OpenAlex: W2009566132
Cited by: 194
References: 47
Citations by year: 2026: 4 · 2025: 1 · 2023: 1 · 2022: 10 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 3 · 2014: 4 · 2013: 6 · 2012: 9
FWCI: 6.65
Type: journal article
Language: en
Open access: green
pure.teikyo.jp
Licence: cc-by-nc-nd
Locations: Endocrinology (publishedVersion)
PubMed (publishedVersion)
Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords: osteoprotegerin, estradiol, estrogen receptor alpha, estrogen receptor beta, estrogen withdrawal, menopause, bone loss, osteoclastogenesis, bone metabolism, estrogen deficiency
MeSH terms: Animals, Cell Line, Dose-Response Relationship, Drug, Estradiol, Glycoproteins, Humans, Kinetics, Receptors, Estrogen, RNA, Messenger, Gene Expression, Stromal Cells, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Estrogen Receptor alpha, Mice, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks